( I )
About
aBOUT US
We are a venture investment firm committed to advancing vaccines and preventive medicine by financing the most critical stages of early development. Our focus is on supporting bioresearch start-ups through pre-clinical research, pre-IND preparation, and FDA Phase I and II clinical trials - the milestones where innovation takes shape and risk-adjusted capital is most needed.
We seek out visionary teams working on novel vaccine platforms, prophylactic biologics, and breakthrough preventive therapies with strong translational potential. By providing both funding and strategic guidance, we help bridge the gap between scientific discovery and clinical validation.
Our investment approach combines rigorous scientific due diligence with deep sector expertise, ensuring our portfolio companies are well-positioned for successful IND filings, regulatory engagement, and progression into later-stage trials. Beyond capital, we offer access to a network of clinical, regulatory, and industry partners who understand the unique challenges of early-stage biopharma development.
We seek out visionary teams working on novel vaccine platforms, prophylactic biologics, and breakthrough preventive therapies with strong translational potential. By providing both funding and strategic guidance, we help bridge the gap between scientific discovery and clinical validation.
Our investment approach combines rigorous scientific due diligence with deep sector expertise, ensuring our portfolio companies are well-positioned for successful IND filings, regulatory engagement, and progression into later-stage trials. Beyond capital, we offer access to a network of clinical, regulatory, and industry partners who understand the unique challenges of early-stage biopharma development.
We believe that the next generation of vaccines and preventive medicines will reshape global healthcare - and we are dedicated to empowering the start-ups driving this transformation
Armen Babadzhanyan
Founder & CEO
Armen Babadzhanyan is a venture investor and entrepreneur with nearly three decades of multi-industry and multi-country leadership experience. As Founder and CEO of MRM BioEnt, he leads investments that bridge biotechnology, healthcare innovation, and advanced industrial systems. His career spans Europe, the Middle East, and Eurasia, combining strategic capital deployment with hands-on operational expertise. Beyond biotech, Armen has built and managed ventures in energy, automation, and manufacturing, driving efficiency and technology integration across sectors. Through MRM BioEnt, he applies this cross-sector experience to advance early-stage therapeutics and research platforms with global scalability and long-term impact.
( III )
Why Us
Our Competitive Advantages
Our team combines decades of experience in vaccine development, regulatory affairs, and early-stage biotech investing. This expertise enables us to evaluate scientific potential with precision and guide founders through complex pre-IND and early clinical pathways.
01
Deep Domain Expertise
We target the most underfunded but critical stages of development - pre-clinical, pre-IND, and FDA Phase I & II-where breakthroughs require catalytic capital to achieve clinical proof-of-concept.
02
Strategic Early-Stage Capital
We specialize exclusively in vaccines and preventive medicine-where the potential for global health impact and market growth converge. This focus allows us to recognize opportunities overlooked by generalist investors.
03
Focus on High-Impact Prevention
Through our partnerships with seasoned FDA advisors, CROs, and clinical trial operators, we help portfolio companies navigate regulatory submissions, site selection, and trial execution with speed and confidence.
04
Regulatory Acceleration Network
We maintain close ties with leading universities, research institutes, and public health organizations, giving our portfolio access to cutting-edge science, licensing opportunities, and collaborative resources.
05
Translational Science Partnerships
While we invest globally, we place a unique emphasis on creating value for the pharmaceutical industry in the Middle East. By connecting our portfolio with regional manufacturing, licensing, and distribution opportunities, we contribute to strengthening local biopharma ecosystems and advancing regional health security.
06
Global Perspective, Regional Impact
Beyond financing, we act as long-term partners-supporting trial design, vendor selection, IP strategy, and preparing companies for follow-on investment or strategic pharma partnerships.
07
Hands-On Value Creation
Our philosophy balances financial returns with measurable outcomes in disease prevention, population health, and healthcare cost reduction-making us the partner of choice for both innovative founders and forward-looking investors.
08
Commitment to Measurable Impact
Our news
